Georgia Bio

Atlanta biotech firm GeoVax raises $1 million in stock sale

05/11/2017

Atlanta biotech firm GeoVax Labs Inc. (OTCQB: GOVX) reported Tuesday it has raised $1 million by selling shares to an unidentified investor in a private placement transaction. In the stock sale, GeoVax sold 1,000 shares of its Series D Convertible Preferred Stock which is initially convertible into 66,666,667 shares of its common stock.

VWR Enters into Definitive Agreement with Avantor

05/09/2017

CENTER VALLEY, Pa. and RADNOR, Pa., May 5, 2017 /PRNewswire/ -- Avantor, a global supplier of ultra-high-purity materials for the life sciences and advanced technology industries, and VWR (NASDAQ: VWR), the major global independent provider of product, supply chain, and service solutions to laboratory and production customers, today announced that they have entered into a definitive agreement under which Avantor will acquire VWR for $33.25 in cash per share of VWR common stock, reflecting an enterprise value of approximately $6.4 billion. The purchase price represents an approximate 17% premium to the unaffected closing stock price on May, 2, 2017, the day prior to the start of market speculation regarding a potential sale of VWR. The purchase price also represents an approximate 20% premium to the 30 trading day volume weighted average price (VWAP), and an approximate 24% premium to the 90 trading day VWAP of VWR common stock as of May 2, 2017.

Invest Georgia: Lt. Governor Cagle Appoints Jeff Muir

05/01/2017

Lt. Governor Casey Cagle has announced Jeff Muir to serve on the Invest Georgia Board of Directors. Invest Georgia is a unique, state-based capital access program, designed to drive business growth and job creation in Georgia.

BD To Acquire Bard For $24 Billion

04/24/2017

FRANKLIN LAKES, N.J. and MURRAY HILL, N.J., April 23, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced today a definitive agreement under which BD will acquire Bard for $317.00 per Bard common share in cash and stock, for a total consideration of $24 billion. The agreement has been unanimously approved by the Boards of Directors of both companies.

IoT-Connected Baby Bottle nfant Reduces Hospital Time, Costs for Preemie Parents

04/19/2017

Approximately 15 million babies — about 1 in 10— are born premature every year, and in the U.S., preterm births are actually rising. Though medical advances are allowing doctors to keep more and more of these babies alive, they often must spend an extended period of time in the Neonatal Intensive Care Unit (NICU), a stay that comes with a high price tag — the average cost for an infant to stay in the NICU is around $3,000 per day.

BIO Statement on MedPAC Vote

04/06/2017

“The patients served under Part B include those fighting cancer, multiple sclerosis, and rheumatoid arthritis—those most vulnerable to disruptions in their treatment regimens. In advance of today’s vote, BIO and many other stakeholders expressed our concerns to MedPAC that the proposals being considered could threaten these vulnerable beneficiaries’ access to critical treatments. We are disappointed, therefore, that the Commission has voted to advance these proposals without addressing those concerns. Reducing provider reimbursement – particularly for small or rural practices – for Part B therapies can disrupt patient access, diminish their health outcomes, and increase overall healthcare expenditures by driving care to more costly and less convenient settings.

BIO Celebrates Five Years of the JOBS Act

04/05/2017

Washington, D.C. (April 5, 2017) – Today the Biotechnology Innovation Organization (BIO) celebrates the fifth anniversary of the Jumpstart Our Business Startups (JOBS) Act, which was signed into law on April 5, 2012. The JOBS Act was designed to enhance capital formation for emerging companies, a vital imperative for growing biotechnology companies seeking to fund the substantial expenses of discovering and developing innovative new medicines.

GaBio and GaBioEd Name Stratford Academy Junior as Georgia BioGENEius Finalist

04/04/2017

Tejas Athni is the 2017 Georgia BioGENEius!

AdvaMed’s Whitaker Urges Congressional Action on MDUFA

04/04/2017

WASHINGTON, D.C. – Advanced Medical Technology Association (AdvaMed) President and CEO Scott Whitaker testified before the Senate HELP Committee today on reauthorization of the Medical Device User Fee Act (MDUFA), stressing the urgent need for Congress to move forward with the agreement as negotiated between FDA and industry.

Sanofi and Regeneron Announce FDA Approval of Dupixent

03/30/2017

BRIDGEWATER, N.J. and TARRYTOWN, N.Y., March 28, 2017 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc.announced today that the U.S. Food and Drug Administration (FDA) approved Dupixent® (dupilumab) Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.

News Posts List